Sphingotec's new biomarker bio-ADM identifies ICU patients who need immediate organ s

[News]

Diagnostics company SphingoTec GmbH today announced a publication in Critical Care1 with data on 2,000 ICU patients demonstrating that sphingotec's proprietary biomarker bio-ADM (Bioactive Adrenomedullin) not only identifies high-risk patients for septic shock at admission but also identifies patients in the general ICU patient population who require immediate life-saving therapeutic intervention.

More... (https://www.news-medical.net/news/20191223/Sphingotecs-new-biomarker-bio-ADM-identifies-ICU-patients-who-need-immediate-organ-support.aspx)